AG
GNMK

Algert Global’s GenMark Diagnostics, Inc GNMK Stock Holding History

Algert Global’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-13,450
Closed -$196K – 576
2020
Q4 		$196K Hold
13,450
– – 0.06% 347
2020
Q3 		$191K Sell
13,450
-5,700
-30% -$87.1K 0.06% 320
2020
Q2 		$282K Buy
+19,150
New +$195K 0.1% 281

Other funds holding GNMK

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Algert Global's GNMK Position: Q1 2021 in Review

Algert Global sold out of GenMark Diagnostics, Inc (GNMK) in Q1 2021, closing a stake of 13,450 shares — an estimated $196K sold.

Algert Global first reported a position in GNMK in Q2 2020 and held it in 3 quarters. The position peaked at $282K in Q2 2020. 164 funds tracked by Wall St. Rank hold GNMK as of Q1 2021.

  • Algert Global reported no remaining GenMark Diagnostics, Inc position as of Q1 2021 after selling out during the quarter.
  • Algert Global sold 13,450 GenMark Diagnostics, Inc shares in Q1 2021, an estimated $196K.
  • Algert Global first reported a position in GenMark Diagnostics, Inc in Q2 2020 and held it in 3 quarters.
  • Algert Global's GenMark Diagnostics, Inc position peaked at $282K in Q2 2020.
  • 164 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q1 2021.

Based on Algert Global's 13F filing for Q1 2021, filed 14 May 2021.